Dysregulated neutrophil extravasation contributes to the pathogenesis of many inflammatory disorders. Pericytes (PCs) have been implicated in the regulation of neutrophil transmigration, and previous work demonstrates that endothelial cell (EC)-derived signals reduce PC barrier function; however, the signaling mechanisms are unknown. Here, we demonstrate a novel role for EC-derived macrophage migration inhibitory factor (MIF) in inhibiting PC contractility and facilitating neutrophil transmigration. With the use of micro-ELISAs, RNA sequencing, quantitative PCR, and flow cytometry, we found that ECs secrete MIF, and PCs upregulate CD74 in response to TNF-a. We demonstrate that EC-derived MIF decreases PC contractility on 2-dimensional silicone substrates via reduction of phosphorylated myosin light chain. With the use of an in vitro microvascular model of the human EC-PC barrier, we demonstrate that MIF decreases the PC barrier to human neutrophil transmigration by increasing intercellular PC gap formation. For the first time, an EC-specific MIF knockout mouse was used to investigate the effects of selective deletion of EC MIF. In a model of acute lung injury, selective deletion of EC MIF decreases neutrophil infiltration to the bronchoalveolar lavage and tissue and simultaneously decreases PC relaxation by increasing myosin light-chain phosphorylation. We conclude that paracrine signals from EC via MIF decrease PC contraction and enhance PC-regulated neutrophil transmigration.-Pellowe, A.
Neutrophil transmigration across the microvascular wall involves coordinated interactions among an inner endothelial cell (EC) lining, the extracellular matrix basement membrane (BM), and BM-embedded pericytes (PCs) (1). During inflammation, TNF-a and other proinflammatory cytokines stimulate EC to increase the expression of adhesion molecules, such as E-selectin, intercellular adhesion molecule 1 (ICAM1), and vascular cell adhesion molecule 1 (VCAM1). After transendothelial migration, neutrophils crawl along a subluminal BM/PC layer until they reach gaps between adjacent PCs, where PCs guide neutrophils toward regions of BM with reduced laminin content (2) .
Growing evidence suggests that PC contractility is a critical regulator of neutrophil transmigration. In contrast to ECs, in which increased cytoskeletal remodeling is required to generate ICAM1-rich actin docking sites and promote neutrophil transmigration (3, 4) , relaxation appears to facilitate neutrophil transmigration through the loss of PC focal adhesions and disassembly of actin stress fibers. PC relaxation may play a role in creating intercellular gaps that serve to expose regions of low laminin expression in the surrounding BM, reducing the BM-PC barrier to allow entry of neutrophils into the surrounding tissue (5, 6) . We have previously demonstrated an important role for ECs in mediating the PC microvascular barrier: transmigration through an EC/PC bilayer is significantly increased compared with transmigration through a PC monolayer alone, and pretreatment of a PC monolayer with TNF-a-activated EC conditioned medium (EC-CM) accelerates neutrophil transmigration (7) . However, the EC-derived signals that reduce PC barrier function are unknown.
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine known to exert significant proinflammatory effects (8) (9) (10) (11) . MIF is expressed by many cell types, including EC. In response to diverse stimuli, MIF is secreted from preformed intracellular pools and can activate multiple signaling pathways by engaging its receptors CD74, CXCR2, or CXCR4. MIF is increased in diseases associated with acute inflammation and injury, including acute lung injury (ALI), and its severe form acute respiratory distress syndrome (ARDS) (12) . ALI/ARDS is characterized by changes in the alveolarcapillary barrier, resulting in lung edema and transmigration of neutrophils into interstitial and alveolar spaces (13) . In ALI/ARDS, MIF is increased in the bronchoalveolar fluid (BALF), in serum, and in lung ECs (8, 14) . High-expression MIF haplotypes convey increased risk of mortality in ARDS, and the neutralization of MIF mitigates ALI severity in multiple murine models, suggesting a causative role for MIF in ARDS progression (8, (14) (15) (16) .
We tested the hypothesis that activated EC-derived MIF is an important signal to promote PC relaxation and therefore, neutrophil transmigration. With the use of in vitro systems of cultured human ECs and PCs from umbilical vein and placental microvessels, respectively, we confirm that EC contraction and PC relaxation promote neutrophil transmigration. We show that TNF-a increases EC secretion of MIF and PC expression of CD74 and that MIF, via engagement of the PC CD74, reduces PC contractility in 2-dimensional biomaterial models. With the use of a biomimetic model of the human microvascular wall and human neutrophils from healthy donors, we demonstrate that EC-PC signaling via MIF-CD74 interactions decreases the PC barrier to neutrophil transmigration. Finally, with the use of a Cre-lox system to generate mice with an EC-specific deletion of Mif, we show that EC-derived MIF regulates PC relaxation and neutrophil transmigration in a murine model of ALI.
MATERIALS AND METHODS

Isolation and culture of human cells
PCs were isolated by explant outgrown from microvessels obtained from de-identified human placenta using previously established methods (17) . Isolated human PCs were phenotyped using flow cytometry to ensure positive staining for anti-human a-smooth muscle actin (aSMA; clone 1A4; Santa Cruz Biotechnology, Dallas, TX, USA), CD90 (clone K-15; Santa Cruz Biotechnology), and neuron glial antigen 2 (clone H-300; Santa Cruz Biotechnology) and negative staining for smooth muscle myosin heavy chain (clone 3F8; Abcam, Cambridge, United Kingdom; Supplemental Fig. S1A-E) . ECs were harvested from de-identified human umbilical veins, according to methods previously described (18) . The isolation and use of cells derived from these materials are classified as not human subjects research by the Yale Human Investigations Committee. ECs and PCs were cultured in tissue culture-treated T75 flasks in M199 medium (Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% fetal bovine serum (Seradigm; VWR International, Radnor, PA, USA) and 1% penicillinstreptomycin (Thermo Fisher Scientific). For EC cultures, media were also supplemented with 10 mg/ml EC growth supplement (Collaborative Biomedical Products, Bedford, MA, USA), and T75 flasks were coated with 0.1% gelatin (MilliporeSigma, Burlington, MA, USA). Confluent flasks were trypsinized with 0.25% trypsin-EDTA (Thermo Fisher Scientific) and resuspended in medium for seeding. Fresh human neutrophils were isolated from the peripheral blood of healthy volunteers, as approved by the Yale Human Investigation Committee (Protocol 0902004786). Peripheral vein blood was drawn into syringes containing citrate phosphate dextrose and 6% dextran (Polysciences, Warrington, PA, USA). Syringes were incubated upright to allow erythrocytes to settle from the plasma. Plasma was subsequently collected and centrifuged for 6 min at 1200 rpm. The cell pellet was resuspended in PBS and layered on a Histopaque 1077 column (MilliporeSigma) and centrifuged for 20 min at 1200 rpm. The neutrophil-enriched pellet was collected and resuspended in PBS and centrifuged once again for 6 min at 1200 rpm. The remaining cell population was resuspended in PBS, supplemented with Mg, Ca, and glucose at a final concentration of 6 3 10 6 cells per milliliter.
In vitro stimulations and pharmacological inhibitor treatments
Vascular cells were treated with 10 ng/ml recombinant human TNF-a (PeproTech, Rocky Hill, NJ, USA) and/or 10 ng/ml recombinant human MIF (BioLegend, San Diego, CA, USA) for 4 h, unless otherwise indicated. The 4-h time point was selected based on previous studies indicating maximal neutrophil transmigration following 4 h of microvascular cell activation (19) . To inhibit contractility via inhibition of myosin II ATPase, PCs were pretreated with 10 mM blebbistatin (BB) (MilliporeSigma) (20) for 1 h, or ECs were treated with 15 mM BB for 10 min before functional studies. To induce contractility, ECs and PCs were both pretreated with the phosphatase inhibitor calyculin A (CA) (1 nM; MilliporeSigma) for 10 min before functional studies. Concentrations and time points were determined based on previous studies. (3, 4, 6, 14, 21) . These treatments do not specifically induce or inhibit contractility, and therefore, we confirmed that the desired inhibition or promotion of cell contractility was induced by BBs and CAs, respectively, and that effects were sustained for the length of neutrophil transmigration experiments (treatment time plus 1 h; Supplemental Fig. S1F-I). To generate EC-CM, ECs were treated with 10 ng/ml TNF-a for 4 h, and medium was collected and transferred to PC cultures. For inhibitor studies, TNF-a EC-CM was supplemented with 10 mg/ml ISO-1 (Milli-poreSigma, Darmstadt, Germany); 50 mg/ml 3-(3-hydroxybenzyl)-5-methylbenzooxazol-2-one, designated MIF098 (Debiopharm, Lausanne, Switzerland); or an equal volume of DMSO before treatment of PC (10, 22, 23) . MIF098 was specifically chosen as a result of its molecular design to target the MIF N-terminal site that interfaces with CD74 (22) .
Neutrophil transmigration
Neutrophil transmigration experiments were performed as previously described (7) . In brief, PC or EC monolayers were cultured on 24-mm polycarbonate transwell inserts with 3-mm pores (Corning, Corning, NY, USA) and upon reaching confluence, were treated according to the conditions previously described. EC/PC bilayers were prepared, as previously described by seeding PCs on the basal side and ECs on the apical side of transwells (7) . Transwell inserts were transferred to 6-well plates coated with 2% agarose, and medium was replaced with nonactivated EC or PC medium. Approximately 3 3 10 6 human neutrophils were added to each transwell and allowed to transmigrate for 1 h (37°C, 5% CO 2 ). Transmigrated neutrophils were collected from the basal chamber of the transwell and counted with a hemocytometer, and transmigration rates were calculated as a percentage of total neutrophils.
Neutrophil adhesion, crawling speed, and persistence
ECs or PCs were cultured to confluence on 25-mm glass coverslips (VWR International) and activated as previously described. Monolayers were washed with 13 PBS (Thermo Fisher Scientific) and transferred into Sykes-Moore adhesion chambers (Bellco Glass, Vineland, NJ, USA). To assess neutrophil adhesion, ;1 3 10 5 human neutrophils were injected into the Sykes-Moore adhesion chamber. Neutrophils were allowed to adhere for 500 s, and the number of neutrophils contacting the monolayer was counted. The adhesion chamber was inverted for 500 s to allow nonadherent neutrophils to fall off the surface, the chamber was reinverted, and the remaining adherent neutrophils were counted by rapidly acquiring 5 random images using the Zeiss Axiovert 200M inverted microscope (Carl Zeiss, Thornwood, NY, USA). Adhesion was calculated as a percentage of total neutrophils.
For crawling speed and persistence assays, neutrophils were similarly injected into Sykes-Moore adhesion chambers and allowed to settle for 5 min before acquiring time-lapse images every 15 s over 30 min using the Zeiss Axiovert 200M inverted microscope (Carl Zeiss). Images were analyzed using MatLab (MathWorks, Inc., Natick, MA, USA) and ImageJ software (National Institutes of Health, Bethesda, MD, USA). Neutrophil centroids were tracked manually using the MTrackJ plugin for ImageJ. Random walk model speed and persistence were calculated using an algorithm written by Nicholas R. Romsey (Iowa State University, Ames, IA, USA) and generously provided by Dr. Ian C. Schneider (Iowa State University) (24, 25) . In brief, single-cell instantaneous speed, S, and directional persistence time, P, were obtained by fitting these to the persistent random walk equation (Eq. 1) using a nonlinear least-squares regression analysis (26) . The sampling time, t, was set to 15 s. Neutrophils that moved at least 10 mm (;1 cell length) from the origin were included for analysis.
micro-ELISA and human MIF ELISA EC and PC monolayers were cultured to confluence, medium was replaced with control or stimulated with or without TNFa-supplemented media, and supernatant was collected and used immediately or stored at 280°C. Supernatants were thawed to room temperature before use. For the micro-ELISA, an antibody array was printed on poly-Lys slides (MilliporeSigma) using the SpotBot Personal Array Printer (Arrayit Corp., Sunnyvale, CA, USA) and the following antibodies: IFN-g, TNF-a, IL-2, IL-4, IL-1b, TNF-b, Rantes, IL-6, IL-10, IL-12, granulocyte macrophagecolony-stimulating factor (GM-CSF), monocyte chemoattractant protein 1, TGF-a, VEGF, MIF IL-5, IL-8, IL-13, IL-7, IL-15, macrophage inflammatory protein (MIP)1a, MIP1b. A polydimethylsiloxane mold was used to create panels around microarrays. Panels were washed with a solution of 3% bovine serum albumin (BSA) in 13 PBS 3 times; then, nonspecific binding was blocked by incubation in 3% BSA in PBS for 2 h at room temperature. Samples were added to panels and allowed to bind for 1 h at room temperature. Panels were washed, and a solution of antibodies was added for 1 h. Panels were washed and incubated in 1 mg/ml streptavidin-allophycocyanin (BioLegend) in 1% BSA in 13 PBS for 30 min in the dark. Panels were washed and allowed to incubate at room temperature in wash solution for 30 min. Slides were rinsed in 13 PBS and Milli-Q water and allowed to dry before scanning. (40 mm) , and at least 10,000 cells were analyzed on an S1000EX STD-13+L flow cytometer (Stratedigm, San Jose, CA, USA). Positive fluorescence was normalized to IgG controls.
Real-time quantitative RT-PCR
PC were stimulated with TNF-a for 0, 4, 8, or 12 h. Cells were then washed with sterile 13 PBS and processed using the RNeasy Mini Kit (Qiagen, Germantown, MD, USA), according to the manufacturer's protocol. The High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) was used to synthesize cDNA from RNA. For CD74, CXCR2, and CXCR4, real-time quantitative RT-PCR reactions were assembled with Taqman Gene Expression Master Mix and predeveloped Taqman geneexpression probes (Thermo Fisher Scientific). Gene-expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase or hypoxanthine-guanine phosphoribosyltransferase 1. For MIF, platelet EC adhesion molecule 1 (PECAM1), and VCAM1, expression was normalized to 18S, and assays were performed using the following primers:
MIF-forward: 59-ATGCCTATGTTCATCGTGA-39 MIF-reverse, 59-TCAAGCGAAGGTGGAACCGTT-39 PECAM1-forward, 59-CCAAGGCCAAACAGA-39 PECAM1-reverse 59-AAGGGAGCCTTCCGTTCT-39 VCAM1-forward, 59-GCCCACTAAACGCGAAGGT-39 VCAM1-reverse, 59-ATGGTCAGAACGGACTTGGAC-39
Contractility assays
For silicone wrinkle assays, 50 ml silicone (30,000 cs; Milli-poreSigma) was spread onto 25-mm diameter glass coverslips (VWR International) and polymerized by briefly passing over a flame. Silicone gels were plasma treated (PlasmaEtch, Carson City, NV, USA), and PCs were seeded at 10% confluence and allowed to adhere overnight. Cells were treated as previously described, 5 images were taken per coverslip, and wrinkles were counted. For 3-dimensional contractility assays, a 2.0 mg/ml collagen solution was prepared by mixing bovine collagen I (Corning) with 4.5% v/v NaHCO 3 (7%, pH 8.5), 6.8% v/v 103 Eagle's minimum essential medium (Lonza Biologics, Portsmouth, NH, USA), and 22% v/v PC suspension (1 3 10 6 cells/ml). The collagen-cell suspension was distributed into 24-well plates (400 ml/well) and incubated at 37°C/5% CO 2 for 24 h before stimulating an additional 24 h. Images were taken, and the area of collagen gels was determined using ImageJ.
Small interfering RNA knockdown
PCs were grown to 70% confluence and treated with an RNAlipid complex using Lipofectamine RNAiMax, as directed (Thermo Fisher Scientific). For contractility assays, PCs were treated with 50 pmol On-TargetPlus human CD74 small interfering RNA (siRNA) or On-TargetPlus nontargeting control siRNA (Dharmacon, Lafayette, CO, USA). Medium was changed after 48 h, and cells were allowed to equilibrate for 24 h before seeding on silicone substrates. For transmigrations, PCs were treated with siRNA, as described for 6 h before seeding on the basal side of transwells. Cells were allowed to equilibrate for 48 h before performing transmigration assays. Knockdown was confirmed for each experiment via real-time quantitative RT-PCR.
Immunofluorescence microscopy
PCs were cultured on 25-mm diameter glass coverslips (VWR International), washed with 13 PBS (Thermo Fisher Scientific), and incubated in 4% PFA for 30 min. Cells were washed with 13 PBS and incubated in 2% BSA for at least 1 h before staining. Cells were incubated in 2% BSA with mouse anti-human paxillin (clone PAX227; BioLegend) overnight at 4°C, rinsed, incubated in 2% BSA with rabbit anti-mouse IgG FITC (MilliporeSigma) for 1 h at room temperature or with rhodamine-phalloidin for 20 min at room temperature (Thermo Fisher Scientific), and mounted with Vectashield with DAPI (Vector Laboratories, Burlingame, CA, USA). For membrane staining, cells were stained with PKH26 Red Fluorescent Cell Linker Kit (MilliporeSigma), according to the manufacturer's protocol. Images were acquired using the Zeiss Axiovert 200M inverted microscope (Carl Zeiss Microscopy). Actin alignment, as a function of anisotropy score, was determined using the FibrilTool plug-in for ImageJ on random rectangular selections per cell, as has been previously described (27, 28) . An anisotropy score of 1 is indicative of perfect alignment, whereas an anisotropy score of 0 is indicative of no alignment. Visible focal adhesions were counted per cell and averaged for n . 5 cells per replicate. PKH26-stained PC monolayers were processed using ImageJ. To quantify gaps, thresholds were adjusted to 10% and used to create binary images that were analyzed using the "analyze particles" function.
Animal models
Animal protocols were reviewed and approved by the Yale University Animal Care and Use Committee. Mice with an EC conditional deletion of Mif were generated by crossing vascular endothelial (VE)-Cre (mice express Cre recombinase under the control of a Cdh5 promoter) with Mif flox/flox mice, denoted EC-MIF-knockout (KO). VE-Cre mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA), and Mif flox/flox mice were generated as previously described by Fingerle-Rowson et al. (58) . All mice used for experiments were 8-12 wk old and were previously backcrossed $10 times on a C57BL/6 background. Littermate MIF flox/flox mice were used as controls in all animal experiments and denoted as EC-MIF-wild type (WT). For LPS lung injury, 50 mg LPS from Escherichia coli (serotype O111:B4; MilliporeSigma) in 50 ml PBS was administered intranasally. Five hours after exposure, mice were anesthetized using urethane (1.8 mg/g body weight), and the trachea was cannulated and perfused with 2 0.8 ml aliquots of cold PBS. The cellular contents and BALF (12) were collected and separated by centrifugation. After obtaining BALF, a 25 G needle of a 1-ml syringe was inserted into the right ventricle, and 0.5 ml blood was collected in heparinized tubes. PBS was flushed through the right ventricle, and PFA (10%) was inserted into the trachea at a pressure of 20 cm H 2 O for 15 min before removing lungs for histology.
Isolation of EC from mouse lungs
EC (CD31 + , CD45 2 ) and hematopoietic cells (CD45 + ) were isolated by magnetic activated cell sorting using Miltenyi Biotec (Bergisch Gladbach, Germany) magnetic columns and corresponding antibodies. Lungs were harvested from mice, sliced to small pieces in PBS on ice, digested in collagenase (0.1%) for 30 min, and filtered through 70-and then 40-mm nylon mesh to make a single cell suspension, and red blood cells were lysed using ammonium-chloride-potassium lysing buffer (Lonza Biologics). Cells were then sequentially incubated with antibodycoated magnetic beads, first with anti-CD45 antibody-coated beads and then with anti-CD31 antibody-coated beads (Miltenyi Biotec). Cells were separated following each incubation with an automated magnetic-activated cell sorting cell separator (Miltenyi Biotec), per the manufacturer's instructions.
Western blot
Cells were lysed in RIPA (MilliporeSigma) buffer, supplemented with proteinase (Thermo Fisher Scientific) and phosphatase inhibitors (Roche, Basel, Switzerland), and the protein concentration was determined using a bicinchoninic protein assay kit (Thermo Fisher Scientific). Western blots were performed on 20-30 mg protein separated by SDS-PAGE, transferred to PVDF membranes, and immunoblotted using the following primary antibodies: anti-phospho-myosin light chain (Ser 19; 3671; Cell Signaling Technology, Danvers, MA, USA) and anti-b-actin (sc47778; Santa Cruz Biotechnology). Horseradish peroxidase-linked anti-goat IgG (sc2020; Santa Cruz Biotechnology) and horseradish peroxidaselinked anti-rabbit IgG (7074; Cell Signaling Technology) were used as secondary antibodies. Proteins were detected by ECL reagents (Thermo Fisher Scientific).
BALF analysis
BALF cells were enumerated with a Coulter Counter (Beckman Coulter, Brea, CA, USA). Slides of BALF cells were prepared for manual counting via cytospin and stained with Hema 3 (Protocol; Thermo Fisher Scientific). BALF cells were washed with 13 PBS and 1% BSA and counted according to conventional morphologic criteria for neutrophils. For flow cytometry, 1 3 10 6 cells were stained with anti-GR1-FITC (RB6-8C5; BioLegend) and anti-CD115 (clone AFS98; eBioscience) for 60 min at 4°C, washed, and resuspended in 1% BSA before analyzing with S1000EX STD-13 flow cytometer (Stratedigm). BALF cytokines were measured using a Luminex-based 23-cytokine assay (Bio-Rad, Hercules, CA, USA). Assays with minimal to no detection were excluded from the heat map (IFN-g, IL-4, IL-5, IL-6, IL-9, and IL-17A). BALF MIF concentrations were measured by sandwich ELISA using specific antibodies, as previously described (29) .
Lung histology
Lung tissue was immediately placed in 4% PFA and incubated overnight at 4°C. The next day, tissue was washed twice with 13 PBS for 30 min and placed in 70% ethanol. In brief, formalin-fixed, paraffin-embedded lung tissue sections were deparaffinized with xylene, rehydrated with graded alcohol solutions, and washed with deionized water. A Giemsa stain was used for neutrophil identification. For immunofluorescent staining, heat-induced antigen retrieval with target retrieval solution (pH 6.0; Dako, Carpinteria, CA, USA) was performed. Sections were blocked with serum-free proteinblocking buffer (Dako) for 30 min and incubated with the following primary antibodies overnight at 4°C: 1) rabbit antiphospho-myosin light chain (p-MLC; ab2480; Abcam), 2) goat anti-CD31 (sc-1506; Santa Cruz Biotechnology), and 3) Alexa Fluor 568-conjugated rabbit anti-platelet-derived growth factor receptor (PDGFR)b (ab206875; Abcam). Samples were washed 3 times by immersion in PBS for 5 min and incubated with the following secondary antibodies for 1 h: 1) Dylight 488-conjugated donkey anti-goat (SA5-10086; Thermo Fisher Scientific), and 2) Alexa Fluor 647-conjugated chicken antirabbit (A21443; Thermo Fisher Scientific). Samples were washed 3 times by immersion in PBS for 5 min and mounted with Prolong Gold mounting medium with DAPI (Thermo Fisher Scientific). Rabbit IgG (Thermo Fisher Scientific) was used as an isotype control. The entire lung was surveyed for each mouse, and 4-6 images were taken from each lung. In each sample, CD31 + vessels with a diameter ,50 mm in the lung perimeter, away from bronchovascular bundles, were identified. Images were acquired with a Leica SP5 (Leica, Wetzlar, Germany). Positive and negative staining of p-MLC were determined by comparing with a negative (isotype) control and a positive (smooth muscle) control, and a subset of data was confirmed by an observer blinded to treatment groups.
Statistical analysis
To normalize for human donor and passage variability, some in vitro statistics are presented as fold change over nonactivated controls and analyzed using a Student's t test. For continuous data, we used nonparametric rank sum tests unadjusted for multiple comparison. Sample size was chosen based on the minimum required for significance based on prior experience. For chemokine data, an ANOVA was used to determine differences in cytokine concentration for each individual cytokine and unadjusted for multiple comparisons. Categorical data were compared with a x 2 statistic. For all tests, 2-sided values of P , 0.05 were considered significant. To visualize cytokine data, sample means for each measured cytokine were subtracted from each data sample, such that the mean of all samples was set equal to 0 for each cytokine. Values were then normalized by multiplying all data for each cytokine by a scale factor S so that the sum of the squares of the values in each row is 1.0. Analyses were performed using Cluster 3 software (bonsai.hgc.jp/;mdehoon/ software/cluster/software.htm), and figures were generated using Java Treeview (30) . For animal studies, sample size was estimated from the effect size of a preliminary experiments.
One replicate was excluded because of technical failure. Graphs and statistical comparisons were performed with GraphPad Prism v.6.00 for Windows (GraphPad Software, La Jolla, CA, USA).
RESULTS
EC and PC contractility alternately regulates neutrophil transmigration and barrier function
Contractile function was altered in EC and PC by treating with BB (myosin II ATPase inhibitor for inhibition of cellular contraction) or CA (phosphatase inhibitor for inhibition of cellular relaxation) to inhibit or promote contractility, respectively (20, 21, 31) . To confirm that functional changes could be induced in ECs and PCs using these pharmacological agents, cells were cultured on deformable silicone substrates, and the number of wrinkles per cell were analyzed as a metric of contractile function ( Fig. 1A-C) . Treatment doses and times were chosen based on previously published literature and proof of sustained functional effects (Supplemental Fig. S1F -I) (3, 4, 32) . As a result of the low basal levels of EC contractility, there was no significant effect of BB treatment alone. CA treatment significantly increases EC contractility (P , 0.01) ( Fig. 1B) . TNF-a-activated EC significantly increase contractility (P , 0.0001), which is inhibited by BB (P , 0.0001; Fig. 1B) . At a basal state, PCs are contractile cells that promote higher levels of silicone wrinkling, and this function could be promoted or inhibited with CA (P , 0.05) or BB (P , 0.0001), respectively (Fig. 1C ). PC activated with TNF-a alone significantly increase contractility (P , 0.05), which can also be inhibited by BB (P , 0.0001; Fig. 1C ).
To understand the effects of EC and PC contractility on neutrophil transmigration, human neutrophils were allowed to transmigrate across EC or PC monolayers pretreated with control medium supplemented with TNFa, TNF-a + BB, or TNF-a + CA. Activation of EC with TNF-a or TNF-a + CA significantly increases neutrophil transmigration to 30 or 35%, respectively (P , 0.01; Fig.  1D ). Inhibition of EC contractility with BB significantly decreases neutrophil transmigration compared with treatment with TNF-a (15 vs. 30%; P , 0.05; Fig. 1D ). In contrast, the opposite effect was observed for PC monolayers. Neutrophil transmigration across PC monolayers pretreated with TNF-a alone or TNF-a + CA was not different from nonactivated PCs (Fig. 1H ). The addition of BB significantly increased transmigration to ;20% compared with both control and TNF-a-activated PCs (P , 0.05), whereas the addition of CA significantly decreased transmigration compared with TNF-a-activated PC (P , 0.05; Fig. 1H ).
As we are primarily interested in the behavior of neutrophils in an inflammatory environment, key steps to the neutrophil adhesion cascade were investigated in EC and PC monolayers activated with TNF-a, with or without BB or CA. The difference in neutrophil transmigration efficiency was not attributed to diminished neutrophil adhesion, crawling speed, or persistence (directional migration; Fig. 1E -G, I-K).
Exogenous MIF-and TNF-a-induced, EC-secreted MIF inhibits PC contractility
Previous work has demonstrated a role for EC-secreted signals as a mediator of PC barrier function, although no specific paracrine signal was identified (7) . Therefore, a micro-ELISA was performed to identify cytokines induced by TNF-a activation of ECs. TNF-a-activated EC significantly upregulate secretion of IL-10, GM-CSF, VEGF, MIF, and MIP1a (Supplemental Fig. S2A ). Analysis of previously published RNA-sequencing data reveals that complimentary receptors for ligands IL-10, GM-CSF, and MIP1a on PCs are not upregulated by TNF-a activation (Supplemental Fig. S2B) (33) . However, the MIF receptor CD74 is significantly upregulated in PC following TNF-a activation, providing a potential target for inflammatory paracrine signaling between ECs and PCs (Supplemental Fig. S2B ).
To confirm initial micro-ELISA results, ELISAs were performed to asses EC and PC MIF secretion. Both ECs and PCs significantly increase MIF secretion after 4 h of TNF-a activation ( Fig. 2A and Supplemental Fig. S2C ). At baseline, EC secretion of MIFs was 3.3-fold higher than PC secretion of MIFs (838 vs. 253 pg/ml; P , 0.05; Fig. 2A ). After activation with TNF-a for 4 h, EC secretion of MIFs was 4-fold higher than PC secretion of MIFs (1574 vs. 382 pg/ml; P , 0.05; Fig. 2A ). Although PCs are larger cells than ECs and contain fewer cells per confluent monolayer, this trend was maintained even after normalizing for cell numbers (Supplemental Fig.  S2C-E) . These data suggest that human ECs, and not human PCs, are the primary source of MIF secretion in inflammatory environments. We confirm that both ECs and PCs express TNF-a receptors 1 and 2 and therefore, differences in MIF secretion are not a result of differential expression of TNF-a receptors (Supplemental Fig. S2F, G) .
We investigated the expression of MIF receptors CD74, CXCR2, and CXCR4 in quiescent and TNF-a-activated human microvascular PCs. Whereas PCs were found to express all 3 receptors, CD74 transcription alone was increased by TNF-a within 12 h of activation ( Fig. 2B-D) . CD74 increased ;2.5-fold after TNF-a activation compared with nonactivated controls (P , 0.05; Fig. 2B ). Flow cytometry confirmed that PC expression of the CD74 surface receptor, but not CXCR2 or CXCR4, is increased after 4 h of TNF-a activation (P , 0.05; Fig. 2E-G ). This suggests that during TNF-a-induced human microvascular inflammation, EC secretion of MIF is temporally associated with an increase in human PC expression of the MIF receptor, CD74.
Given the role of PC contractility in regulating neutrophil transmigration, we sought to determine whether ECderived MIF promotes or inhibits PC contraction via the CD74 receptor. PCs were cultured on deformable silicone substrates, and the number of silicone wrinkles per PC were analyzed as a metric of contractility following TNFa-activation for 4 h (Fig. 2H ). TNF-a significantly increased the number of wrinkles generated by PCs compared with nonactivated controls (P , 0.05). In contrast, the addition of BB reduced PC contractility compared with both nonactivated and TNF-a-activated PC (P , 0.0001; Fig. 2I ). The addition of exogenous MIF to TNF-a-activated PC significantly reduced the number of wrinkles compared with TNF-a-activated PC (P , 0.01; Fig. 2I ). Nonactivated PC do not alter their contractility in response to MIF treatment (Supplemental Fig. S3A ). Next, we investigated the effect of EC-secreted factors by treating PCs with nonactivated or TNF-a-activated EC-CM, with or without the addition of the synthetic MIF antagonist ISO-1 or the small molecule inhibitor of MIF-CD74 binding, MIF098. As was observed with exogenous MIF, TNF-a EC-CM significantly reduced the number of wrinkles compared with nonactivated EC-CM (P , 0.01; Fig. 2J ). ISO-1 or MIF098 attenuated this response and eliminated differences from PCs treated with nonactivated EC-CM or significantly increased the number of wrinkles compared with TNF-a-activated EC-CM treatment alone (P , 0.05), whereas the vehicle control did not (Fig. 2J) . To assess the dependence of MIF-mediated relaxation on the expression of CD74, PCs were treated with either siRNA targeting the CD74 receptor or nontargeting siRNA as a control, and PC contractility was investigated following TNF-a activation and MIF exposure. PC transcription of CD74 was reduced by ;80% (Fig. 2K ). PCs treated with nontargeting siRNA behaved as previously observed, increasing contractility in response to TNF-a-activation (P , 0.05) and decreasing contractility with the addition of MIF (P , 0.05; Fig. 2L ). PCs treated with CD74 siRNA adopted a contractile phenotype in response to TNF-a (P , 0.001; Fig. 2L ), but in contrast, MIF-mediated reduction in contractility was diminished. With the loss of the CD74 receptor on PCs, we saw for the first time that PCs in the TNF-a + MIF treatment were more contractile than nonactivated controls (P , 0.05; Fig.  2L ). Furthermore, the comparison of PCs treated with nontargeting siRNA with those treated with CD74 targeting siRNA shows that there is no difference in the nonactivated and TNF-a-activated groups, but there is a statistically significant increase in the number of wrinkles generated by PCs treated with TNF-a + MIF after CD74 knockdown (P , 0.05; Fig. 2L ).
PCs in vivo are embedded within a 3-dimensional BM composed of collagens and laminins. To assess the ability of MIF to inhibit PC contractility in a biomimetic 3-dimensional model, PCs were embedded in 2 mg/ml collagen gels, and the final gel areas were compared following 24 h of activation (Supplemental Fig. S3 ). Treatment with TNF-a + BB or TNF-a + MIF significantly increased gel area and thus, reduced cell contractility compared with nonactivated PCs (P , 0.0001, P , 0.01; Supplemental Fig. S3C ). The addition of ISO-1 and MIF098, but not vehicle control, following treatment with TNF-a EC-CM reduced contractility compared with PCs treated with nonactivated EC-CM (P , 0.01; Supplemental Fig. S3D ). These data suggest that EC-derived MIF via PC-CD74 inhibits PC contractility in both a 2-and 3dimensional cell-culture model.
Exogenous MIF and TNF-a EC-CM reduces p-MLC, actin stress fiber assembly, and focal adhesion formation in TNF-a-activated PC
PC contractility is associated with p-MLC, stress fiber formation, and focal adhesion formation. To investigate whether MIF-dependent changes in PC contractility are mediated by changes in p-MLC, Western blotting was used to determine levels of p-MLC relative to b-actin after 4 h of PC activation. TNF-a significantly increased p-MLC compared with nonactivated controls after 4 h (P , 0.01), and PCs coactivated with TNF-a + MIF decreased p-MLC by ;33% compared with TNF-a alone (P , 0.05; Fig. 3A, B) .
To determine whether or not actin fiber assembly was altered in PCs treated with TNF-a + MIF, cells were immunostained with rhodamine-phalloidin, and F-actin fiber alignment was quantified as a measure of stress fiber formation ( Fig. 3C-F) . There was no difference in actin alignment between nonactivated and TNF-a-activated cells. However, the addition of BB or MIF to TNFa-activated cells significantly decreased actin fiber alignment compared with both nonactivated (P , 0.001) and TNF-a-activated (P , 0.01; Fig. 3E ) PC. Interestingly, there was no change in aSMA alignment in any of the PC-stimulated conditions, suggesting that acute regulation of PC contraction is not attributed to aSMA (Supplemental Fig. S4A ). PCs treated with TNFa EC-CM had significantly decreased actin anisotropy compared with PCs treated with nonactivated EC-CM (P , 0.01; Fig. 3F ). This effect could be restored by ISO-1 or MIF098, which significantly increased actin anisotropy compared with TNF-a EC-CM-treated PC (P , 0.0001) but was not restored by DMSO control (Fig. 3F) .
PCs were immunostained for paxillin to quantify the number of focal adhesions per cell. There were significantly more focal adhesions per cell in TNF-a-activated PCs compared with nonactivated PCs (P , 0.05), and even the addition of low levels of MIF was sufficient to reduce focal adhesions compared with nonactivated and TNFa-activated PCs (P , 0.01-P , 0.001; Fig. 3G ). TNF-a + BB treatment significantly reduced the number of focal adhesions per cell compared with nonactivated and TNFa-activated PCs (P , 0.001; Fig. 3G ). Likewise, PCs treated with TNF-a EC-CM had significantly fewer focal adhesions per cell than cells treated with nonactivated EC-CM (P , 0.0001; Fig. 3H ). This phenotype was partially rescued by the addition of ISO-1 (P , 0.001 vs. nonactivated EC-CM) and completely rescued by the addition of MIF098 (P , 0.0001 vs. TNF-a EC-CM) but not by the vehicle control (Fig. 3H) . These data demonstrate that EC-derived MIF 
Exogenous MIF and TNF-a EC-CM increase PC-PC gap formation and neutrophil transmigration across PC monolayers and EC/PC bilayers
MIF is released from ECs within 4 h of TNF-a activation, consistent with its role in early immunity. There is evidence that intercellular PC-PC gaps can regulate barrier function and neutrophil transmigration; therefore, PCs were activated with TNF-a alone or in combination with BB or MIF for 4 h to investigate the effects of MIF-induced relaxation on PC-PC gap formation. Following activation, PC monolayers were fixed and labeled with the membrane dye PKH26. Analysis of intercellular gaps demonstrated no difference in the number of gaps in quiescent PC monolayers and those activated with TNF-a. However, the addition of either BB or MIF to TNFa-activated PCs significantly increased the number of gaps per field of view compared with nonactivated (P , 0.0001) and TNF-a-activated (P , 0.01, P , 0.05) PC (Fig. 4A, B) . Differences in gap formation were not attributed to differences in cell density (Supplemental Fig. S4B ).
We investigated whether the visible changes in PC-PC gaps correlated with differences in neutrophil transmigration. In agreement with previous work, both nonactivated and TNF-a-activated PC permit low levels of neutrophil transmigration (12.0 and 12.1%; Fig. 4C) (19) . The addition of either BB or MIF to TNF-a-activated PC monolayers increased neutrophil transmigration by ;1.5fold (17.6 and 17.1%) compared with nonactivated controls (P , 0.01, P , 0.05) and TNF-a-activated PC (P , 0.01, P , 0.05; Fig. 4C ). PCs were also treated with EC-CM to determine if EC paracrine signals induce the same increase in neutrophil transmigration. PCs treated with nonactivated EC-CM permit the same low level of Figure 4 . PC monolayers and EC/PC bilayers demonstrate increased neutrophil transmigration in response to MIF-CD74 signaling. A) PCs were activated with control or TNF-a-supplemented medium, with or without BB or MIF for 4 h, fixed, dyed (nuclei, blue; cell membrane, PKH26), and segmented to create binary images of PC-PC gaps (original scale bars, 100 mm). B) Gaps per field of view (FOV) were quantified (n = 3 independent experiments). C, D) PC monolayers on porous (3 mm) polycarbonate transwells were activated with PC medium (C ) or EC-CM (D) for 4 h, and neutrophils were allowed to transmigrate for 1 h (n = 4 independent experiments). E, F ) Transmigration experiments were repeated across EC/PC bilayers (E) (n = 4 independent experiments), as well as EC/PC bilayers using PCs treated with nontargeting or CD74-targeting siRNA (F ) (n = 4 independent experiments). Box plots represent 10th-90th percentile. # P , 0.05 vs. nonactivated, *P , 0.05 vs. TNF-a (nonparametric ANOVA or 2way ANOVA); #, *P , 0.05, ##, **P , 0.01, ***P , 0.001, ####, ****P , 0.0001. transmigration as was seen across nonactivated PCs (11.8%; Fig. 4D ). Activation with TNF-a EC-CM increased neutrophil transmigration by 1.6-fold (18.7 and 19.3%; P , 0.05; Fig. 4D ). The addition of either ISO-1 or MIF098, but not vehicle control, to TNF-a EC-CM before PC activation caused a significant decrease in neutrophil transmigration compared with TNF-a EC-CM alone (15.7 and 15.0%, P , 0.05; Fig. 4D ). These data are consistent with the hypothesis that MIF, present in TNF-a EC-CM, is a critical factor mediating PC relaxation and enhanced neutrophil migration across PC monolayers in vitro.
As a biomimetic model of the microvascular wall, ECs were cultured on the apical face of transwells with PCs on the basal face to create EC/PC bilayers. Neutrophil transmigration was quantified across EC/PC bilayers, and in accordance with previously published work, TNF-a activation increased neutrophil transmigration by ;2-fold relative to nonactivated controls, from 12.5 to 23.7% (P , 0.0001; Fig. 4E ). The addition of either ISO-1 or MIF098 significantly reduced transmigration compared with both nonactivated (P , 0.01; P , 0.05) and TNF-a-activated (P , 0.001; P , 0.0001) conditions, to 16.3 and 15.1%, respectively ( Fig. 4E) . In contrast, the addition of DMSO as a control had no effect, and neutrophil transmigration was sustained at high levels (20.9%; Fig. 4E ).
To confirm the role of MIF-CD74 signaling in PCmediated neutrophil transmigration, EC/PC bilayers were cultured using PCs treated with nontargeting or CD74targeting siRNA, and neutrophil transmigration was quantified. When PCs were treated with nontargeting siRNA, TNF-a activation significantly increased transmigration across EC/PC bilayers from 8.3 to 21.8% (P , 0.01; Fig. 4F ), as expected. This difference was attenuated when PCs were treated with CD74 siRNA (Fig. 4F) . Together, these data implicate MIF-CD74 signaling in PCs as a mechanism, whereby PCs actively regulate neutrophil transmigration in both PC monolayers and EC/PC bilayers.
EC-MIF-KO mice are protected from LPSinduced neutrophil infiltration to the lungs
The in vivo relevance of EC-derived MIF and its regulation of PC barrier function in acute inflammation have not been previously examined. To do so, we generated the first EC conditional MIF-KO mouse using lox-cre systems. Conditional MIF KO mice (Mif flox/flox ) were mated with mice possessing a Cre-recombinase under the control of an endothelial-specific promoter, VE cadherin (VE-Cre), to generate a novel deletion of endothelial-derived MIF (Mif flox/flox VE-Cre), denoted as EC-MIF-KO. EC deletion of MIF was confirmed by quantitative RT-PCR (Supplemental Fig. 5A, B) . EC-MIF-KO mice and EC-MIF-WT mice were challenged with either intranasal LPS or PBS (sham) (34) . Five hours after LPS inhalation, BALF was collected, and neutrophils were identified by flow cytometry using a GR-1 + /CD115 2 gating strategy (Fig.  5A) . Whereas EC-MIF-WT mice showed a significant increase in neutrophil infiltration from LPS challenge compared with sham (P , 0.001), EC-MIF-KO mice had significantly fewer neutrophils in BALF in response to LPS than the EC-MIF-WT mice (P , 0.05; Fig. 5B and Supplemental Fig. S5C, D) . Tissue samples from both EC-MIF-KO and EC-MIF-WT mice challenged with LPS had significantly more neutrophils in the alveolar and interstitial spaces than PBS-treated controls (P , 0.01; P , 0.0001; Fig.  5C, D) . However, the number of neutrophils in the alveolar and interstitial spaces was significantly lower in the LPStreated EC-MIF-KO lungs compared with the LPS-treated EC-MIF-WT lungs (P , 0.001; Fig. 5C, D) . To ensure that differences in neutrophil infiltration to the BALF and tissue were not attributed to changes in the overall level of circulating neutrophils, blood was collected, and circulating neutrophils were quantified using a GR-1 + /CD115 2 gating strategy. Whereas there was an increase in the number of circulating neutrophils in LPS-compared with sham-treated mice for both EC-MIF-WT and EC-MIF-KO (P , 0.0001; P , 0.01), there was no significant difference in the number of neutrophils in the blood of EC-MIF-WT and EC-MIF-KO mice within the LPS-treated groups (Fig. 5E ). Cytokine levels in the BALF were also evaluated to determine if neutrophil transmigration was related to chemotaxis. With the exception of IL-6, all other cytokines, including MIF, were not different between EC-MIF-KO and EC-MIF-WT mice treated with LPS (Supplemental Fig. S6A, B) .
To evaluate the association between the EC-MIF-KOprotective phenotype and PC contractility, lung tissue was costained for microvascular ECs (CD31), and PCs (PDGFRb), and p-MLC (Fig. 6A) . With the use of a binary counting system to identify microvessels with positive staining for PC p-MLC, we determined that EC-MIF-WT lungs, but not EC-MIF-KO lungs, had a significant decrease in the percent of p-MLC-positive PCs after LPS challenge, indicating that the loss of EC-MIF reversed this phenotypic change (P , 0.001; Fig. 6B ). EC-MIF-KO lungs maintained ;70% of PC p-MLC after LPS challenge, demonstrating a significant increase compared with EC-MIF-WT lungs (P , 0.01; Fig. 6B ). Overall, these data suggest that the loss of EC-MIF is protective against neutrophil infiltration in an acute inflammatory model via the restoration of microvascular barrier function and p-MLCpositive PCs.
DISCUSSION
Studies in mice have recently revealed an important role for PCs as regulators of neutrophil transmigration (2, 6, 32) . However, in vivo studies are often too complex to identify mechanisms that drive cellular function (35) . Therefore, the aim of this study was to reduce the complexity of PC-mediated neutrophil transmigration by use of an in vitro model consisting of 3 primary human cells (ECs, PCs, and neutrophils). We demonstrate for the first time that EC and PC contractility alternatively regulate neutrophil transmigration, whereby inhibition of contractility decreases EC-mediated neutrophil transmigration but enhances PC-mediated transmigration (Fig. 1) . These data show that ECs are the primary human microvascular cells responsible for MIF secretion in response to TNF-a activation and that CD74, the MIF receptor, is upregulated on PCs by TNF-a activation. Together, this allows ECs and PCs to respond to TNF-a in a coordinated manner that enables modulation of the microvascular barrier (Fig. 2 ). Both exogenous MIF and EC-derived MIF induce PC relaxation through the CD74 receptor, which is associated with a reduction in p-MLC, actin stress fiber alignment, and focal adhesion formation (Fig. 3) . Decreased PC contractility reduces barrier function and enhances neutrophil transmigration (Fig. 4) . Finally, the role of EC-derived MIF was evaluated in vivo using a novel, conditional EC-MIF-KO mouse. Neutrophil transmigration was decreased, and PC contractility was increased in EC-MIF-KO mice compared with controls following intranasal LPS ( Figs. 5 and 6 ). Together, these data suggest that EC-PC paracrine signaling, through MIF-CD74 interactions, reduces PC contractility and PC-mediated impedance of neutrophil extravasation during acute inflammation.
During acute inflammation, TNF-a activates EC to enhance the secretion of EC-derived cytokines (19, 36, 37) . We demonstrate that both human EC and PC secrete MIF under basal conditions and after activation with TNF-a ( Fig. 2A) . Recent work has reported an increase in PC secretion of MIF in response to TNF-a, which we confirm, although these changes are modest relative to EC MIF secretion within a time course that corresponds with acute inflammation and neutrophil recruitment (38) . Moreover, outside of the CNS, most microvessels contain 10-fold or more ECs compared with PCs (39) . The in vitro findings suggest that ECs are the primary microvascular cells responsible for TNF-a-mediated secretion of MIF and that human PCs secrete relatively low levels of MIF in both quiescent and inflammatory environments. Rather than serving as primary producers of MIF, PCs appear to be a primary target of MIF action.
In addition to the release of inflammatory signals, microvascular ECs and PCs both regulate neutrophil transmigration through F-actin-mediated mechanisms. Specifically, TNF-a activation induces EC actin remodeling that promotes the formation of docking structures rich Figure 5 . EC-MIF-KO mice are protected from LPS-induced neutrophil extravasation in an ALI model. A, B) BALF was collected from EC-MIF-WT and EC-MIF-KO mice subject to either LPS or sham treatment, and a GR-1 + , CD115 2 gating strategy was used to quantify neutrophil infiltration [n = 6 (4 females, 2 males) for sham treated; n = 12 (Cre + ) to 14 (Cre 2 ; 6-7 females, 6-7 males) for LPS treated]. C, D) Lung tissue was collected, and a Giemsa stain was used to visualize and quantify neutrophils [n = 4 (2 females, 2 males) for sham treated; n = 9 (5 females, 4 males) for LPS treated]. Original scale bars, 50 mm. E ) Blood was collected from EC-MIF-WT and EC-MIF-KO mice subject to either LPS or sham treatment, and neutrophils were counted by flow cytometry using the same gating strategy as for BALF [n = 7 (3 females, 4 males) for sham treated; n = 9-10 (4 females, 5-6 males) for LPS treated]. HPF, high-power field. All bars represent means and SE. *P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001 (nonparametric ANOVA).
in ICAM1 and VCAM1, which envelop transmigrating neutrophils to support transmigration. Contractile forces have also been implicated in the formation of EC-EC gaps; however, neutrophil transmigration through these gaps in vivo is disputed (3, 4, 36, 37, (40) (41) (42) . Alternatively, PC relaxation, loss of focal adhesions, and disassembly of stress fibers are proposed mechanisms for PC shape change that increases intercellular PC gaps and neutrophil transmigration. Importantly, PCs do not create the actin/ ICAM1-rich docking sites characteristic of inflamed ECs (6, 19) . We confirm here that inhibition of EC contractility is correlated with decreased neutrophil transmigration (Fig.  1D ). Interestingly, increases in intercellular PC gaps have been linked with inflammatory TNF-a activation in vivo, despite in vitro evidence that TNF-a activation increases PC contractility (2, 43) . This discrepancy may be attributed to the complex multifactorial signaling that occurs between ECs and PCs in vivo compared with a single TNF-a activation in vitro. In the present study, data show that TNF-a activation alone causes PC contraction, whereas TNF-a + MIF and TNF-a EC-CM both decrease PC contraction (Fig. 2) . With the use of combinatorial TNF-a and MIF activation, we have created a more representative model of the inflammatory microenvironment, suggesting that in vivo findings of TNF-a-induced PC relaxation are partly mediated by TNF-a actions on ECs.
Cells in close contact with extracellular matrices can interact through biochemical and mechanical signaling that occurs both from cell to matrix and from matrix to cell (44) . PCs are embedded within the BMs they share with ECs, and interactions between PCs and the BM contribute to vascular health and inflammation (28, 45) . Specifically, we observe that relaxation of PCs induces shape change that increases the size of intercellular PC-PC gaps in vitro.
In vivo, this process may serve to expose underlying lowexpression regions in the BM to promote neutrophil transmigration (2, 32) . We demonstrate that both MIF and TNF-a EC-CM induce PC relaxation and PC modification of silicone polymer models, suggesting that MIF-mediated PC relaxation may play a role in inflammatory remodeling of the microvascular BM (Fig. 1) . Wrinkle generation in silicone substrates by cell contraction correlates with the Young's modulus of the contracting cell, and areas lying directly on a wrinkle exhibit a local cell stiffness of ;16 kPa, ;2-fold higher than on areas of PCs not associated with wrinkles (46) . This difference in local mechanics suggests that the generation of forces required to wrinkle a soft substrate are mediated by individual cell stiffening, commonly attributed to local actin polymerization and cytoskeletal reorganization. The wrinkling of silicone substrates was observed despite low-density PC cultures, implying relevance for contractile function in a variety of organs in which PC density can vary from ;1:1 to 1:100 relative to ECs (39) . F-actin bundling to form stress fibers and association with actin binding proteins, such as paxillin, are well described mediators of cell contractility and can occur as fast as 1 min after activation (47, 48) . Our data demonstrate that acute changes in PC contractility are correlated with changes in focal adhesions and stress fiber formation but not with aSMA structure (Supplemental Fig. S3 ) (49, 50) . A similar phenomenon has been observed in vascular smooth muscle cells, in which phenotypic characterization of traditional contractile markers, such as aSMA, is not sufficient for determining contractile phenotype (51) .
Neutrophil transmigration through ECs facilitates subsequent transmigration through PC monolayers, and EC/ PC bilayers support significantly increased transmigration compared with PC monolayers (7, 19) . Interestingly, the addition of EC paracrine factors from EC-CM to PC cultures before neutrophil transmigration is sufficient to upregulate neutrophil transmigration across PC monolayers. This suggests that EC-neutrophil signaling is not the only interaction mediating barrier function and that EC-PC crosstalk is important to reduce the barrier created by PCs. We confirm the significance of EC-PC paracrine signaling in the present study and identify EC-MIF and PC-CD74 as a mechanism to regulate PC barrier function and neutrophil transmigration in acute inflammation (Fig. 4C, D) . MIF can activate ECs, PCs, and neutrophils and can act on multiple cellular receptors, and although we confirm that MIF-CD74 neutralizing MIF098 attenuates TNFa-mediated neutrophil transmigration across EC/PC bilayers (Fig. 4E) , we sought to determine a definitive role of MIF-CD74 signaling in microvascular barrier function. First, we demonstrate that MIF-induced relaxation is partly mediated through PC expression of the CD74 receptor. In response to TNF-a + MIF, PCs treated with CD74-targeting siRNA significantly increased wrinkle generation compared with PCs treated with a nontargeting siRNA. Furthermore, despite the complexity of the EC/PC bilayer system, in which 3 primary human cell types are cultured together, we note that even an 80% reduction in the PC receptor CD74 is sufficient to inhibit TNFa-mediated increases in neutrophil transmigration (Fig. 4F ). While we do not rule out a role for MIF receptors CXCR2 and CXCR4, neither of these receptors is upregulated by TNF-a activation of PCs, and functional studies investigating a role for these receptors in neutrophil transmigration are complicated as a result of their role as a neutrophil receptor for MIF, whereas neutrophils do not express CD74 (52) .
To confirm the relevance of these studies in vivo, we have demonstrated for the first time that EC-MIF-KO mice are partially protected against LPS-induced inflammation and are less permissive to neutrophil transmigration ( Fig.  5 ). p-MLC is increased in PDGFRb-positive PCs from EC-MIF-KO mice, suggesting that the proposed in vitro mechanism may be occurring in vivo (Fig. 6 ). Previous work has demonstrated an important role for MIF in inflammatory conditions, such as ALI (8, 53) . However, the mechanisms by which MIF mediates its effect in these diseases have not been completely understood. We herein identify a novel mechanism by which EC-MIF signals to PC-CD74, providing a potential therapeutic target in ARDS, a disease in which the mortality has remained ;40% for the past 20 yr (54) (55) (56) .
A limitation of this work is the inability to perform experiments in a PC-specific CD74 conditional KO mouse, as no such mouse has been generated. The use of a CD74 global KO is a poor substitution as a result of the ubiquitous expression of CD74 and its multifaceted role as both a MIF receptor and as a chaperone for major histocompatibility complex II antigen presentation. Furthermore, the lack of a single PC-specific marker complicates the ability to target microvascular PCs while minimizing off-target effects. We acknowledge that MIF is a pleiotropic cytokine, and it is difficult to determine to what extent EC-MIF via PC-CD74 is mediating the above findings. Yet, the data make a strong argument for the role of EC-PC paracrine signaling as an important mediator of inflammatory function. MIFs may have direct effects on EC barrier function; however, we demonstrated that the direct application of MIFs to PCs is sufficient to increase neutrophil transmigration (57) . MIF is also a known neutrophil chemokine; however, we prepared PC monolayers by replacing activated medium with untreated medium before neutrophil transmigration. Therefore, no chemokines were present in the medium during transmigration for any of the conditions tested, and the increase in neutrophil transmigration is a consequence of EC-PC paracrine signaling. Additionally, neutrophils do not express appreciable cell surface receptor CD74, and the use of specific MIF-CD74 chemical inhibitors abrogated neutrophil transmigration (52) . Our data demonstrate that MIF induces a loss of p-MLC in vitro, whereas in vivo, the loss of EC MIF is associated with increased p-MLC in PCs. We found no difference in circulating neutrophils or levels of inflammatory cytokines, including MIF, in the BALF of LPS-treated EC-MIF-WT and EC-MIF-KO mice, indicating that neutrophil transmigration was not an effect of changes in circulating neutrophils or cytokine deficiency ( Fig. 5 and Supplemental Fig. S6 ).
In summary, we demonstrate for the first time that human EC and PC contractility differentially regulate neutrophil transmigration. We show that human ECs are the primary source of TNF-a-induced MIF secretion in the microvasculature and that human microvascular PC correspondingly upregulate the MIF receptor CD74. We have identified a role for decreased p-MLC in MIF-induced PC relaxation that allows PCs to dynamically remodel their microenvironment in both 2 and 3 dimensions. This subsequently results in a loss of PC barrier function and an increase in neutrophil transmigration, a result that was replicated both in vitro with human microvascular cells and in vivo with a novel, EC-specific MIF KO model of acute inflammation.
